Date: 2011-03-10
Type of information: Commercialisation agreement
Compound: Veregen® ointment (made from the extract of green tea leaves - catechins)
Company: MediGene (Germany) Will-Pharma (Belgium)
Therapeutic area: Gynecology - Infectious diseases
Type agreement: commercialisation
Action mechanism:
Disease: External genital warts
Details: MediGene has signed an exclusive license and supply agreement with Will-Pharma for the commercialization and marketing of Veregen® ointment in Belgium, the Netherlands and Luxembourg. Will-Pharma will market, promote and distribute the drug for the treatment of genital warts. MediGene has already entered into several marketing partnerships for Veregen®, e.g. with Nycomed for the USA, with Abbott for Germany, Austria, and Switzerland, with Expanscience for France, with Juste for Spain and Portugal as well as with a number of other partners across Europe, Latin America and Asia. MediGene is planning to continue this global licensing strategy.
Financial terms: Financial details of the agreement were not disclosed.
Latest news:
